Skip to main content
. 2021 Sep 30;11(10):988. doi: 10.3390/jpm11100988

Figure 1.

Figure 1

Prognostic value of the RNA-seq-based risk score. (A) Maxstat defined cut-point and prognostic value of RNA-seq-based risk score in CoMMpass cohort (n = 674 MM patients). The RNA-seq risk score split MM patients into low- and high-risk groups in two independent cohorts: (B) CoMMpass and (C) Montpellier (n = 76 MM patients) (OS, Kaplan–Meier curves). (D) RNA-seq-based risk score value calculated in normal human B to plasma cell differentiation and in malignant plasma cells from MM patients (n = 129) and HMCLs (n = 33). Wilcoxon test. NS: nonsignificant, * p-value < 0.05, ** p-value < 0.01, **** p-value < 0.0001.